Under the agreement, NU100 will be generated at Catalent’s facility in Brussels, Belgium, where the injectable product will be formulated, filled and packaged in a prefilled syringe.
Nuron Biotech is currently planning to accelerate NU100 into Phase III clinical trials in 2011.
Catalent Business Development vice president Sheila Dell said the company is excited to have the opportunity to apply its sterile delivery expertise to support Nuron through this complex and important stage of product development.
"In addition to preparing and supplying NU100 for Phase III clinical trials, we are pleased to be able to support commercial manufacturing during the product’s first three years on the market," Dell said.
Catalent’s Sterile Technologies business offers development, clinical and commercial manufacturing services for sterile injectables and sterile Blow-Fill-Seal products.